Head-to-head · WeighScore
Lumen Meds vs Omada Health
The verdict
Lumen Meds takes it — 64.4/100 to 55.6/100.
Lumen Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lumen Meds (lumenmeds.com) is a Delaware-incorporated compounded GLP-1 telehealth platform (Lumen Meds LLC, 128 Sunset Blvd #1214, New Castle, DE 19720).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Lumen Meds | Omada Health |
|---|---|---|
| WeighScore | 64.4/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #243 | #436 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | $196/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #243 · C
Strengths
- LegitScript Certified
- Free expedited cold shipping — important for GLP-1 cold-chain integrity
- Lifestyle coaching included, not just medication dispensing
- Orders labs when needed
- Named legal entity (Lumen Meds LLC, Delaware) with a physical address
Where it loses points
- $0 first-month promo — verify recurring billing and cancellation terms before committing
- Standard ongoing semaglutide price not shown (only the first-month promo)
- Per-state availability not listed
- Pharmacy partners not named
- Health quiz required before you see final per-patient pricing
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.